Products
FluoTech Biosciences is at the forefront of innovative nanomaterial solutions, offering cutting-edge products designed to revolutionize cardiovascular health and biomedical research.
Overview
Atherosclerosis is a chronic cardiovascular disease characterized by plaque buildup in arteries, restricting blood flow and increasing the risk of heart attacks and strokes.
FluoTech Biosciences is focused on developing ATHRICINE, an advanced therapeutic solution for atherosclerosis. Utilizing our proprietary FTB-728 nanoparticle platform, ATHRICINE offers targeted drug delivery to reduce plaque buildup and inflammation.
Our Collaborations
FTB-728
Proprietary MOF-based nanoparticle with high drug-loading capacity and customizable properties.
ATHRICINE
Targeted therapy for atherosclerosis using FTB-728 nanoparticle drug delivery platform.
FTB-728
Proprietary MOF-based nanoparticle with high drug-loading capacity and customizable properties.
Our proprietary FTB-728 nanoparticle platform is engineered for unparalleled drug-loading capacity (up to 77.5%) and precise controlled release. This versatile technology serves as both a therapeutic delivery platform and a research material, enabling targeted drug delivery while minimizing systemic exposure.
- High drug-loading capacity
- Customizable surface chemistry
- Inherent fluorescence and MRI contrast properties
- Room-temperature storage
ATHRICINE
Targeted therapy for atherosclerosis using FTB-728 nanoparticle drug delivery platform.
ATHRICINE is an advanced therapeutic solution for atherosclerosis, leveraging FTB-728 to deliver anti-inflammatory drugs directly to disease sites. Enhanced by PEGylation and peptide targeting, ATHRICINE offers superior efficacy in plaque regression and reduced side effects compared to traditional treatments.
- Targeted drug delivery to inflamed endothelial cells
- Controlled release kinetics for sustained efficacy
- Potential to reduce residual cardiovascular risk
- Compatibility with existing clinical workflows
